Business
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
PITTSBURGH, March 06, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage company developing product candidates that treat
About this update from Cognition Therapeutics, Inc.
[{"type":"text","content":"PITTSBURGH, March 06, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), is presenting results of proteomic and correlation analyses of two completed clinical studies at the AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference (March 5-9, 2024 in Lisbon, Portugal). The three posters, which are listed below, summarize proteomic analyses from the completed SEQUEL and SPARC studies, which were conducted in adults with mild-to-moderate Alzheimer’s disease. VIRTUALIdentification of New Pharmacodynamic Biomarkers of CT1812 that Correlate with Favorable Functional Connectivity of the Brain Di Caro V, Pandey K, Cho E, Duong D, de Haan W, Grundman M, Seyfried N, Caggiano AO, Vijverberg EG, Hamby ME. (e-Poster) MARCH 6-7Analysis of CSF Samples from a Phase 2 Clinical Trial in Alzheimer’s Patients Show that CT1812 can Modulate α-synuclein Di Caro V, Pandey K, Duong D, Seyfried N, Grundman M, Vijverberg EG, Caggiano AO, Teunissen C, Hamby ME. (Poster shift 1 – 0164) MARCH 8-9Plasma Proteomic Analysis from Alzheimer's Patients in SPARC Clinical Trial to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812 Lizama B, Duong D, Pandey K, Di Caro V, Mecca A, O’Dell R, van Dyck C, Grundman M, Caggiano AO, Seyfried N, Hamby ME. (Poster shift 2 – 0140) Two posters summarize proteomic analyses from the Phase 2 SEQUEL study which measured the impact of CT1812 on synapse function as determined by changes in brain wave patterns recorded by quantitative electroencephalogram (EEG). These posters identify candidate protein biomarkers that correlate with improvements observed in SEQUEL participants treated with CT1812, Cognition’s lead candidate. Among the proteins identified, those that were strongly correlated with CT1812 treatment effects were associated with protein trafficking, autophagy, neuroinflammation and microglial response. The third poster summarizes proteomic analyses from the Phase 1 SPARC study, which was designed to measure the impact of CT1812 on synaptic density. Pathways identified in these proteomic analyses support a role for CT1812 in modulating Aβ biology and neuroinflammation, among other disease-relevant processes. “Analyses of CSF samples from these studies build on our e...